FF-10502, an Antimetabolite with Novel Activity on Dormant Cells, Is Superior to Gemcitabine for Targeting Pancreatic Cancer Cells
The journal of pharmacology and experimental therapeutics/The Journal of pharmacology and experimental therapeutics